Looks like an exciting 2013 from the J.P. Morgan Healthcare Conference

12 of 40

Suzanne Bruhn, CEO of Promedior

Suzanne Bruhn joined Promedior in May and immediately moved from the Philadelphia area to Boston. Bruhn spent 13 years with Shire and served as the senior VP for strategic planning and program management before moving into her first CEO role at Promedior, which is focused on a pipeline of drugs for fibrosis. Fibrosis is a part of many diseases, including potential blockbuster areas such as lung fibrosis, but Promedior is currently focused on the rare fibrotic conditions myelofibrosis and idiopathic pulmonary fibrosis (IPF). The area of orphan diseases, Bruhn told us, speaks to her personally. "Making something incrementally better than the two drugs before it doesn't interest me," she said.